Indivior Pharmaceuticals (INDV) Total Current Liabilities (2021 - 2026)

Indivior Pharmaceuticals' Total Current Liabilities history runs 6 years deep, the most recent figure standing at $779.0 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 22.49% year-over-year to $779.0 million in Q1 2026; TTM through Mar 2026 was $779.0 million, a 22.49% decrease from a year earlier, with the FY2025 full-year figure at $914.0 million, down 1.08% from the prior year.
• Total Current Liabilities retreated to $779.0 million in Q1 2026 per INDV's latest filing, from $914.0 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $1.3 billion in Q4 2023 and bottomed at $779.0 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $985.0 million (2025), against an average of $992.9 million.
• Across the five-year window, Total Current Liabilities gained 26.74% in 2022 and decreased 27.87% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $1.0 billion in 2022, then grew by 25.71% to $1.3 billion in 2023, then dropped by 27.87% to $924.0 million in 2024, then declined by 1.08% to $914.0 million in 2025, then fell by 14.77% to $779.0 million in 2026.
• Per Business Quant, the three latest INDV Total Current Liabilities figures stand at $779.0 million (Q1 2026), $914.0 million (Q4 2025), and $965.0 million (Q3 2025).